microRNA-based biomarkers for diagnosis of ALS-FTD

Short title: miRNA biomarkers for ALS-FTD

Iddo Magen[1,2, $], Nancy-Sarah Yacovzada[1,2, $], Jason D. Warren[3], Carolin Heller[3,4], Imogen Swift[3,4], Yoana Bobeva[5], Andrea Malaspina[5,6], Jonathan D. Rohrer[3*] Pietro Fratta[6*] and Eran Hornstein[1,2*]

1   Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel

2   Department of Molecular Neuroscience, Weizmann Institute of Science, Rehovot, Israel

3 Dementia Research Centre, and 4 UK Dementia Research Institute, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

5 Centre for Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

6 Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK

$ Equal contribution

* To whom correspondence should be addressed: a.malaspina@ucl.ac.uk; j.rohrer@ucl.ac.uk; p.fratta@ucl.ac.uk; eran.hornstein@weizmann.ac.il;

Abstract word count: 154

Text word count (excluding title page, abstract, references and figure legends): 5290

No. of items (Figures, Tables, Supplementary items): 8, 2, 6

References: 102

Abstract

The neurodegenerative disorders amyotrophic lateral sclerosis (ALS) and frontotemporal

dementia (FTD) reside on a clinical and pathological continuum. Heterogeneity in clinical

presentation too often delays clinical diagnosis and calls for molecular biomarkers to assist

diagnosis, including cell free microRNAs (miRNA). However, nonlinearity in the relationship of

miRNAs to clinical states and underpowered cohorts has limited research in this domain. Here,

we prospectively enrolled a large cohort of 495 subjects with ALS (n=202) and FTD (n=168), or

non-neurodegenerative controls (n=125). Based on cell-free plasma miRNA profiling by next

generation sequencing and machine learning approaches, we develop nonlinear prediction

models that accurately distinguish ALS and FTD from non-neurodegenerative controls in ~90%

of cases. Among the miRNAs that contribute to classifying disease, we identified miRNAs

shared between conditions as well as disease-specific miRNAs. The fascinating potential of

diagnostic miRNA biomarkers might enable early-stage detection and a cost-effective screening

approach for clinical trials that can facilitate drug development.

Introduction

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two neurodegenerative diseases that reside along a clinico-pathological continuum (Ling *et al*, 2013; Majounie *et al*, 2012; Neumann *et al*, 2006; Renton *et al*, 2011; Strong *et al*, 2017; van Es *et al*, 2017). ALS is primarily a disease of the human motor neuron system, resulting in muscle atrophy, paralysis and death (Al-Chalabi & Hardiman, 2013; Hardiman *et al*, 2011; Robberecht & Philips, 2013), whereas FTD is characterized by frontal and temporal lobe atrophy, and typically manifests with behavioral or language deficits (Strong *et al.*, 2017).

Shared neuropathological inclusions of the RNA-binding proteins TAR DNA-binding protein 43 (TDP-43) (Neumann *et al.*, 2006) and shared causative genes, chromosome 9 open reading frame 72 (*C9ORF72*), *TARDBP* (TDP-43), *VCP* and *TBK1* (Abramzon *et al*, 2020; Conforti *et al*, 2021), further resonate with comorbidity and clinical symptoms of both diseases in 10-20% of patients. Thus, one in five ALS patients meets the clinical criteria for a concomitant diagnosis of FTD, and one in eight FTD patients is also diagnosed with ALS. However, there are also unique mutations to each disease entity. For example, mutations in heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) cause ALS, but not FTD (Andersen & Al-Chalabi, 2011; Chen *et al*, 2013; Cirulli *et al*, 2015; Peters *et al*, 2015; Renton *et al.*, 2011), and mutations in progranulin (GRN), and charged multivesicular body protein 2B (CHMP2B) may cause FTD but not ALS.

The diagnosis of ALS is currently based on medical history, clinical examination and exclusion of mimicking disorders. Full-blown ALS is easily diagnosed by trained practitioners, however the diagnostic process often takes 1-1.5 years, since progressive deterioration, indicating both upper and lower motor neuron involvement, is required to define ALS. FTD can also be difficult to diagnose, due to heterogeneity in clinical presentation (McKhann *et al*, 2001). Three main phenotypes of FTD are described: behavioral variant frontotemporal dementia (bvFTD), characterized by changes in social behaviour and conduct, semantic dementia (SD), characterized by the loss of semantic knowledge, leading to impaired word comprehension, and progressive non-fluent aphasia (PNFA), characterized by progressive difficulties in speech production (McKhann *et al.*, 2001; Snowden *et al*, 2002).

Brain imaging and several biofluid proteins have been proposed as biomarkers for both ALS and FTD (Al Shweiki *et al*, 2019; Ashton *et al*, 2021; Bellini *et al*, 2022; Benussi *et al*, 2019; Bian *et al*, 2008; Borroni *et al*, 2015; Bourbouli *et al*, 2017; Bright *et al*, 2019; Chouliaras *et al*, 2022; Das *et al*, 2022; Delaby *et al*, 2020; Eratne *et al*, 2022; Feneberg *et al*, 2018; Forgrave *et al*,

2019; Goncalves *et al*, 2017; Gonzalez-Garza *et al*, 2018; Hansson *et al*, 2019; Hu *et al*, 2013;

Jiskoot *et al*, 2019; Katisko *et al*, 2021; Katisko *et al*, 2020; Krishnan *et al*, 2022; McCarthy *et al*,

2018; Meeter *et al*, 2017; Meeter *et al*, 2018; Niikado *et al*, 2019; Oeckl *et al*, 2022; Prado *et al*,

2018; Rossi *et al*, 2018; Sheikh-Bahaei *et al*, 2017; Silva-Spinola *et al*, 2022; Teunissen *et al*,

2016; Thijssen *et al*, 2022; Turner *et al*, 2009; van der Ende *et al*, 2020; Verde *et al*, 2021;

Wilson *et al*, 2022; Xu *et al*, 2016). Among the proteins, noticeable are neurofilament light chain

(NfL), TDP-43 and, phospho-tau, amyloid beta and glial fibrillary acidic protein (GFAP). In this

context, a recent study concluded that high NfL blood levels are indicative of the intensity of

neurodegeneration or the extent of the degenerated axons in both ALS and FTD (Ashton *et al*.,

2021) but cannot contribute to the distinction between these two diseases.

miRNAs are a class of small, non-coding RNAs, that can be quantified in biofluids in a

massively parallel fashion, yielding fine-grained profiles (Coenen-Stass *et al*, 2018). miRNAs

play important roles in ALS pathogenesis and in motor neuron survival (Eitan & Hornstein, 2016;

Emde *et al*, 2015; Haramati *et al*, 2010; Reichenstein *et al*, 2019) and we have previously

shown the power of cell-free miRNAs as biomarkers in neurodegeneration (Magen *et al*, 2022;

Magen *et al*, 2021). Plasma miRNAs were also suggested as diagnostic biomarkers for ALS

(Banack *et al*, 2020; Benigni *et al*, 2016; Cloutier *et al*, 2015; de Andrade *et al*, 2016; Joilin *et al*,

2019; Ravnik-Glavač & Glavač, 2020; Ricci *et al*, 2018; Saucier *et al*, 2019; Sheinerman *et al*,

2017; Takahashi *et al*, 2015; Toivonen *et al*, 2014; Waller *et al*, 2017a; Wang & Zhang, 2020) or

FTD (Denk *et al*, 2018; Grasso *et al*, 2019; Kmetzsch *et al*, 2021; Muller *et al*, 2016; Piscopo *et*

al, 2018; Schneider *et al*, 2018; Sheinerman *et al*., 2017; Sproviero *et al*, 2021; Tan *et al*, 2021).

However, definitive markers have not been reported so far and initial biomarker studies were

confounded by cohort size, sample heterogeneity biased or pre-selection of candidate miRNA.

Furthermore, diagnosis of comorbid ALS-FTD patients with miRNAs has not been pursued.

In this study, we profiled blood plasma miRNAs (Coenen-Stass *et al*., 2018), in a cohort of 533

subjects and developed miRNA-based classifiers for diagnosing ALS and FTD. We

implemented ensemble machine learning approach, to address biomarker nonlinearity and were

able to expose unrevealed disease-associated signals. The diagnostic power of the study roots

from unbiased miRNA signature in a large and heterogeneous meta-cohort, and is validated in

an independent held-out cohort according to the TRIPOD guidelines (Collins *et al*, 2015).

Therefore, circulating miRNAs hold a fascinating potential as diagnostic biomarkers and as

means for patient stratification in clinical trials.

Results

We sought to determine the overall diagnostic capability of miRNA measurements in ALS and
FTD. To this end, we based our study on analysis of plasma miRNA expression and the
development of computational diagnostic models. The initial cohorts included a total of 533
participants, enrolled between 2009 and 2019, with clinical follow up time that ranged between 3
and 66 months. Summary of participants' basic characteristics are described in Table 1.

Quality control of data

We have performed next generation RNA sequencing for all samples and subjected miRNA
data to quality control steps prior to prediction model development. We observed a younger
mean age in both ALS controls (mean age 49.9±13, 95% CI [47.2- 52.5]) and in FTD controls
(mean age of 61±13, 95% CI [57-64]), whereas in other groups the mean age was around 65
(Figure S1). Since both ALS and FTD symptoms manifest late in life, with median disease onset
at 55 and 58 years of age, respectively, we reduced age-variance by excluding 38 participants
younger than 40, which reduced differences in mean age across the remaining meta-cohort of
495 subjects by 33%. Thus, 168 out of 169 FTD patients and 202 out of 206 patients with ALS
were included in the analysis along with 125 out of 158 non-neurodegenerative control samples
(Table S1). We then verified that a merged dataset of ALS and FTD controls, collected in two
different clinical centers does not introduce biases, using Kullback–Leibler divergence measure
and a t-distributed stochastic neighbor embedding (t-SNE) analysis (Figure S2A). This enabled
analysis of all control data in a unified manner. ALS and FTD cases did not differ from the
merged control group, or from each other (Figure S2B).

Out of the >2000 miRNA species that were aligned to the genome, only 132 fulfilled QC criteria.
Next, we quantified the differential miRNA levels in ALS, FTD and control samples (Figure 1A-
C), noting miRNAs that may distinguish ALS and FTD from control and from one another.

Development of binary classifiers for the diagnosis of ALS or FTD

We first established a baseline single-disease predictor for either ALS or FTD. A diagnostic
prediction model for FTD was developed on a randomly selected training set of 135 FTD cases
and 84 controls, comprising 75% of the total cohort (168 cases, 125 controls). As a replication
cohort, the remaining 25% of the data were held out for model validation (33 FTD, 41 control
samples).

The 132 miRNAs were tested as potential predictors, using an ensemble machine learning approach. miRNAs were ranked by their predictive value in the diagnosis of FTD, vs. individuals that did not suffer from neurodegeneration and considered healthy. For selecting the most predictive features during model development, we used *Recursive Feature Elimination* (RFE), an efficient approach that removes miRNAs (features) iteratively to identify those that contribute the most to prediction accuracy (Figure 2A). RFE obtained a set of 13 miRNAs with highest feature importance. The 13-miRNA-based predictor presented a mean receiver operating characteristic area under the curve (ROC AUC) of 0.9, by internal cross validation (Figure 2B). Furthermore, the 13-miRNA-based predictor was capable of predicting the diagnosis of FTD in an independent held-out (replication) cohort of 74 individuals with an ROC AUC of >0.9 (Figure 2C) and an average precision of 0.9. At a defined probability threshold (0.6), the classifier exhibits a 0.8 precision (PPV) with a 0.85 recall (sensitivity), a 0.87 specificity and a 0.2 false discovery rate values. The model is well calibrated and satisfactorily performs on held-out data (Figure 2D, E). Furthermore, a family of models trained with only a subset of the 13 most predictive features, displays a stable AUC ROC performance and reassures that the selected final features are suitable (Figure 2F). In summary, we determined 13 miRNAs that are able to call the diagnosis of FTD with high accuracy.

We then sought to better understand the prediction model by investigating the relative effect of each individual miRNA. Therefore, we utilized post-hoc SHapley Additive exPlanations (SHAP) feature importance analysis to uncover the contribution of individual miRNAs to the FTD diagnostic predictor (Figure 3A, B). The key predictor revealed by SHAP is the astrocyte-derived exosomal miR-361 (Bu *et al*, 2020). Little is known about other miRNAs contributing to prediction.

We further tested individual miRNAs as single predictors of FTD diagnosis. The ROC analysis revealed maximal AUC values of ~0.69 for miR-423-5p and miR-125b-5p (Table S2). In conclusion, 13 miRNAs are able to call the diagnosis of FTD with high accuracy.

Similarly, an ALS-prediction model was developed by ensemble machine learning with RFE, using data from 149 ALS cases and 96 controls (training set). 53 ALS and 29 controls were held-out as an independent replication (validation) cohort. Following a computational RFE approach comparable to that developed for FTD (in Figure 2A), we depicted 12 miRNAs with the highest feature importance (Figure 4A). The predictor developed with these 12 miRNAs presented a mean ROC AUC of 0.86, by internal cross validation (Figure 4B). Furthermore, that 12-miRNA-based predictor was capable of predicting the diagnosis of ALS in an independent

held-out (replication) cohort of 82 individuals with an ROC AUC of 0.78 (Figure 4C). The ALS
model is sufficiently calibrated and a family of models, trained with only a subset of the 12 most
predictive features, displays a stable AUC ROC performance (Figure 4 D-F). With a defined
probability threshold set to 0.45, the classifier obtained a 0.81 precision (PPV) with a recall
(sensitivity) of 0.98 over 0.94 specificity and a 0.19 false discovery rate.

SHAP feature importance analysis uncovered the contribution of miR-206 and miR-1-3p, two
homologous muscle-expressed miRNAs, that were reported to increase in the blood of ALS
patients (de Andrade *et al.*, 2016; Malacarne *et al*, 2021; Raheja *et al*, 2018; Tasca *et al*, 2016;
Waller *et al*, 2017b). Likewise, miR-103a and miR-181b-5p are enriched in brain tissue and in
spinal cord tissues (Ludwig *et al*, 2016), and miR-181b-5p has been proposed as a prognostic
marker for ALS (Magen *et al.*, 2021). In addition, we tested the diagnostic ability of each
individual miRNAs as single predictors in terms of ROC AUC, which revealed predictive value at
the range of 0.75 for miR-186-5p (maximal value) and down to 0.39 for miR-320a (minimal
value, Table S3). We conclude that some individual miRNAs can be used on their own, however
miRNA cooperative predictive value provides a superior performance (>0.78 vs. ~0.75 AUC
ROC).

Development of multi-class predictor of ALS and FTD Diagnosis

Multi-disease classifiers may display improved performance by solving a single optimization
problem, while exploiting a larger meta-cohort. Such classifiers can take into account the
varying levels of relationships that may exist among the different disease entities. Additionally, a
predictor that is potentially able to compare ALS and FTD may be informative about the
molecular biomarker interpretation of the FTD-ALS continuum (ALS-FTD)(Strong *et al.*, 2017).

We established a meta-cohort composed of 495 subjects, with measurements of 132 miRNAs
that passed QC. Then, we applied RFE on to the meta-cohort to reveal 16 miRNAs useful for
creating a ternary classifier (ALS vs. FTD vs. healthy, Figure 6A). The multi-disease classifier
achieved a weighted mean "one-vs-all" ROC AUC of 0.9 across all folds for all classes during
training (Figure 6B) and a weighted "one-vs-all" AUC-ROC of 0.88 on untouched replication
cohort (AUC ROC 0.76, 0.86, 0.97 for controls, ALS, FTD, respectively, Figure 6C). The model
obtained sensitivity of 0.92/0.83, specificity of 0.95/0.79 and an NPV of 0.96/0.88 for FTD/ALS,
respectively (Table 2). We also computed AUC ROC metric for one-vs-one classification,

according to the Hand & Till algorithm (Hand & Till, 2001): FTD vs controls 0.88, ALS vs
controls 0.74, FTD vs ALS 0.97.

In addition, we tested the performance of each of the 16 most predictive miRNAs as single
predictors (Table S4) and present the confusion matrices (Figure 6D, E). One miRNA, miR-185-
5p, is used to predict both ALS and FTD (Figure 6F). Three other miRNAs, not selected in any
of the binary single-disease models, are exclusively selected in the multi-disease model (miR-
24-3p, miR-148a-3p and miR-339-5p, Figure 6F).

SHAP feature importance analysis uncovered the contribution of individual miRNAs to the multi
disease predictor (Figure 7A, B, C). The most predictive miRNA, miR-1-3p, is shown to equally
influence predicting FTD and ALS, while having only a minor contribution in predicting 'controls'
class (Figure 7B,C). miR-206, which is a muscular miRNA like miR-1-3p, is the most predictive
in ALS, with almost no predictive capacity in the FTD model. Similarly, miR-361 mostly
contribute to risk of FTD. This suggests shared miRNAs that are robust features that may be
biologically relevant to the ALS-FTD continuum.

Finally, we tested whether miRNA plasma miRNA classifiers reported in previous works
(Kmetzsch *et al.*, 2021; Sheinerman *et al.*, 2017) perform equally to, better or worse than our
classifiers in the training and held out datasets. Combination of miR-34a-5p, miR-345-5p, miR-
200c-3p and miR-10a-3p, selected previously (Kmetzsch *et al.*, 2021), was consistently inferior
to our classifiers in distinguishing between FTD and controls, ALS and controls, and FTD and
ALS, with lower AUC values (Figure 8). Similarly, the classifiers selected in Sheinerman et al.,
2017 (42) were inferior to our panels of miRNA classifiers. Thus, when tested in comparison to
reported miRNA classifiers from the literature, our panels of miRNA classifiers perform better,
with AUC values ≥0.78 and in some cases exceeding 0.9.

In summary, we have shown that a panel of <16 miRNAs can distinguish between patients with
ALS or FTD and non-degeneration controls, as well as between ALS, FTD and controls, in a
multiclass model.

Discussion

The need to facilitate the diagnosis of neurodegeneration, in early disease stages and in the
face of clinical heterogeneity, raises the hope for new effective biomarkers for ALS and FTD.
Biomarkers may further inform about the comorbidity risk within the ALS-FTD continuum (Strong
et al., 2017)

Circulating miRNAs hold a fascinating potential as diagnostic biomarkers that were not fully
addressed to date. By using a large cohort of 495 subjects, an unbiased, next generation
sequencing approach and advanced computational methods, we overcome limitations of past
works in developing biomarkers for neurodegeneration. First, we overcome the specificity
problem recently reported for NfL. Since NfL levels are high in many neurodegenerative states,
it cannot distinguish ALS from FTD (Ashton *et al.*, 2021). In addition, within miRNA biomarker
development, our binary classifiers are more precise than published predictors (Kmetzsch *et al.*,
2021; Sheinerman *et al.*, 2017). In addition, we develop a multi-disease miRNA predictor model
for ALS and FTD.

The use of gradient boosting trees, an ensemble learning approach, allows discovering miRNAs
that are in a nonlinear relationship with the disease status. Machine-learning classifiers gain
affirmation by cross validation in the training dataset. Furthermore, our models are externally
validated on held-out data, which was not used during feature selection and model
development, according to the TRIPOD guidelines (Collins *et al.*, 2015).

The multi-disease model learns about related (but different) diagnostic tasks, and jointly selects
features for all tasks. This way sample size is increased, features-to-sample ratio of the data is
reduced and yet the particularities of each data set are kept (Azencott, 2020). In the selection of
features, the multi-disease model is intentionally optimized to separate between ALS and FTD
by penalizing for features that enhance disease misclassification and prioritizing miRNAs that
are differentially measured. This is deciphered when the relative contribution of individual
features to the predictive model unfolds by SHAP analysis (Lundberg *et al*, 2020).

We revealed that 16 miRNAs are able to classify FTD, ALS or healthy controls, most of which
are disease-specific (e.g., miR-206 for ALS and miR-361 for FTD). Interestingly, the most
predictive miRNAs are abundant in the neuromuscular and immune systems, which is
conceivable, as neuronal loss, muscle atrophy and neuro-inflammation, come into play in these
pathologies.

According to the human miRNA tissue atlas (Ludwig *et al.*, 2016), most of the selected miRNAs

are CNS-enriched (let-7c-5p/7i-5p, miR-23b-3p, miR-26a-5p, miR-103a-3p, miR-107, miR-125b-

5p, miR-148a-3p, miR-181b-5p, miR-185-5p, miR-320a, miR-339-5p, miR-379 and miR-484), or

muscle-enriched (miR-1-3p, miR-26a-5p, and miR-206).

miR-26a, miR-326, miR-484 and miR-361 were associated with FTD diagnosis in our data and

with cognitive deficits or Alzheimer's disease (AD) in other analyses (Allach El Khattabi *et al*,

2020; Chang *et al*, 2017; Cogswell *et al*, 2008; Goncalves *et al*, 2019; He *et al*, 2020; Ludwig *et*

al, 2019; Wingo *et al*, 2020). In mice, miR-326 inhibited tau phosphorylation, a hallmark of FTD

(He *et al.*, 2020). Interestingly, miR-326, miR-484 and miR-361 contributed to FTD diagnosis

more than to ALS diagnosis.

miR-23b improved cognitive impairments in a rat model of traumatic brain injury (Sun *et al*,

2018) and alleviated neuronal apoptosis (Chen *et al*, 2014). Brain-enriched miR-107 was

selected as predictor in the FTD model and in the multi-disease model, and was also implicated

in AD (Muller *et al*, 2014; Nelson & Wang, 2010; Prendecki *et al*, 2019; Wang *et al*, 2020; Wang

et al, 2008; Yilmaz *et al*, 2016).

miR-206 and miR-1-3p are muscle-derived miRNAs, that were shown to increase in the blood of

ALS patients (de Andrade *et al.*, 2016; Malacarne *et al.*, 2021; Raheja *et al.*, 2018; Tasca *et al.*,

2016; Waller *et al.*, 2017b), presumably as a result of muscle tissue breakdown. Accordingly,

both miRNAs were selected as predictive features in the ALS and multiclass models but not the

FTD model. However, when breaking out the contribution of these two miRNAs to the diagnosis

of ALS, FTD and controls, miR-206 specifically contributes to the diagnosis of ALS, but not of

FTD, while the plasma levels of miR-1-3p contribute to prediction of both diseases in the

multiclass model. According to the SHAP analysis, it seems that low levels of miR-1-3p

contribute to the diagnosis of FTD plausibly by distinguishing it from high levels of miR-1-3p in

ALS.

Let-7c and miR-326 are associated with suppression of neuroinflammation (Ni *et al*, 2015; Zhao

et al, 2019). Changes in blood levels of miR-326, miR-26a, and miR-629 are associated with

multiple sclerosis (MS), a disease that results from autoimmune neuroinflammation, (Baulina *et*

al, 2018; Dolati *et al*, 2018; Honardoost *et al*, 2014; Lindberg *et al*, 2010; Niwald *et al*, 2017;

Regev *et al*, 2018; Sharaf-Eldin *et al*, 2017; Yang *et al*, 2014). Moreover, serum miR-629 was

negatively correlated with MS patient brain volume and lesion severity, respectively (Regev *et*

al, 2017). Thus, some of our miRNA predictors are associated directly or indirectly with

neuroinflammation, a process which occurs in both FTD and ALS.

We would like to put forward a few notable limitations: as is the case with machine learning, the
study is limited in providing mechanistic insight for the measured changes in cell-free miRNA
levels and why defined nonlinear patterns are strongly predictive of disease states.
Discrepancies from conclusions of past studies (Denk *et al.*, 2018; Grasso *et al.*, 2019;
Kmetzsch *et al.*, 2021; Piscopo *et al.*, 2018; Sheinerman *et al.*, 2017) are plausibly related to
the progress we present in power (larger cohort) and to our unbiased analysis that contrasts
past biased choice of miRNA candidates. While we kept held-out cohort for external validation,
towards clinical diagnostic usage, it is warranted to test the predictor on an independent cohort
of different ethnicity. In addition, the documentation of FTD patients with neuromuscular
symptoms and of ALS patients with behavioral symptoms is limited and reduced our ability to
investigate the full range of information at the ALS-FTD continuum.

In summary, we have found specific molecular miRNA patterns that can contribute to diagnosis
of FTD and ALS. These patterns are further alluding to differences and commonalities in the
underlying molecular changes in the ALS - FTD continuum. Therefore, the work encourages
testing if circulating miRNAs biomarkers can be used as a cost-effective screening approach to
increase speed or precision in the diagnosis of suspected neurodegenerative states, thereby
allowing early-stage detection of high-risk individuals prior to inclusion in prospective clinical
trials. More broadly, the findings demonstrate the importance of integrating machine learning
into clinical biomarker studies, addressing nonlinearity and exposing otherwise cryptic disease-
associated signals.

Methods

Standard protocol approvals, registrations, and patient consents

Approvals were obtained from the local research ethics committee and all participants provided

written consent (or gave verbal permission for a carer to sign on their behalf). For ALS samples,

recruitment, sampling procedures and data collection have been performed according to

Protocol (Protocol number 001, version 5.0 Final – 30th November 2015).

Participants and Sampling

Demographic data of study participants are detailed in Table 1. ALS samples and their

respective healthy controls (N = 206 and 102, respectively) were obtained from the ALS

biomarker study. ALS patients were diagnosed according to standard criteria by experienced

ALS neurologists. Healthy controls were typically spouses or relatives of patients.

FTD subjects and their respective controls were enrolled in the longitudinal FTD cohort studies

at UCL. Study cohort included 169 FTD patients and 56 healthy controls.

Blood was collected by venipuncture in EDTA tubes, and plasma was recovered from the whole

blood sample by centrifugation and stored at −80°C until RNA extraction subsequent small RNA

next generation sequencing. Frozen plasma samples of ALS, FTD and controls from the UCL

Biobanks were shipped to the Weizmann Institute of Science for molecular analysis.

Study Design

We determined the sample size by the following power analysis: 150 controls and 150 cases

(either ALS or FTD) are required to obtain an ROC AUC of 0.7 with a power of 99% and a p-

value of 0.0001. Phenotypic data on de-identified patients was separated and blinded during

steps of the molecular analysis.

Small RNA Next Generation Sequencing

Total RNA was extracted from plasma using the miRNeasy micro kit (Qiagen, Hilden, Germany)

and quantified with Qubit fluorometer using RNA broad range (BR) assay kit (Thermo Fisher

Scientific, Waltham, MA). For small RNA next generation sequencing (RNA-seq), libraries were

prepared from 7.5 ng of total RNA using the QIAseq miRNA Library Kit and QIAseq miRNA

NGS 48 Index IL (Qiagen), by an experimenter who was blinded to the identity of samples.

Samples were randomly allocated to library preparation and sequencing in batches. Precise

linear quantification of miRNA is achieved by using unique molecular identifiers (UMIs), of

random 12-nucleotide after 3' and 5' adapter ligation, within the reverse transcription primers

(Coenen-Stass *et al.*, 2018). cDNA libraries were amplified by PCR for 22 cycles, with a 3'
primer that includes a 6-nucleotide unique index, followed by on-bead size selection and
cleaning. Library concentration was determined with Qubit fluorometer (dsDNA high sensitivity
assay kit; Thermo Fisher Scientific, Waltham, MA) and library size with Tapestation D1000
(Agilent). Libraries with different indices were multiplexed and sequenced on NextSeq 500/550
v2 flow cell or Novaseq SP100 (Illumina), with 75bp single read and 6bp index read. Fastq files
were de-multiplexed using the user-friendly transcriptome analysis pipeline (UTAP) (Kohen *et*
al, 2019). Human miRNAs, as defined by miRBase (Kozomara & Griffiths-Jones, 2014), were
mapped using the GeneGlobe pipeline (https://geneglobe.qiagen.com/us/analyze). Sequencing
data were normalized with DESeq2 package (Love *et al*, 2014) under the assumption that
miRNA counts followed negative binomial distribution and data were corrected for the library
preparation batch in order to reduce its potential bias.
330
Constructing Cohorts and Biases Associated with the Data-gathering Process
Each disease cohort has been utilized for building and validating a single-disease (binary)
classifier that can be used as an applicative predictor for clinicians. Then, a meta-cohort, a
unified case-control cohort for both ALS and FTD disease, was constructed to be used for
development and assessment of a multi-disease risk prediction model. As our dataset is
observational and generated by fusion of few study cohorts, we particularly considered bias
associated with the data-gathering process. First, we verified that the control cohorts are not
coming from an underlying different population using t-SNE analysis following batch correction
and DESeq2 normalization. We then performed QC on the age distribution of subjects and
thereby excluded 38 participants younger than 40, to reduce differences in mean age across the
different cohorts. A higher prevalence of males among ALS patients (59%, vs. 31 % in controls)
was observed. This reflects the higher prevalence of ALS in males than in females, as reported
previously (Collaborators, 2018). Therefore, to eliminate the confounding effect, resulting from
statistical relationship between sex and ALS status, the sex variable was removed from the list
of candidate predictors. A higher prevalence of males among FTD patients (65%) than among
the controls (31%) was observed as well. Hence, sex was removed from the list of candidate
predictors to eliminate confounding biases.
348
Verifying de-separation of non-degeneration control cohorts
We established a cohort of 158 non-neurodegenerative controls. Since they originated from two
repositories, Queen Mary hospital (N=102) and University College London from (N=56), we first

verified that the two sets (distributions) can be considered together and that they do not impose
biases, based on the biorepository from which they were collected. Non-neurodegenerative
controls from Queen Mary hospital are presented in light blue (ALS), while controls from
University College London are presented in red. The t-distributed stochastic neighbor
embedding (t-SNE) analysis reveals that both control distributions could have been sampled
from a single population (Figure S1). The Kullback–Leibler divergence, a measure of difference
between probability distributions, indicating a small difference between the two sets in question
(KL = 0.283). Therefore, control samples were unified and considered as a single meta-cohort
for analysis of miRNA abundance, without introducing additional sampling biases.
361

Gradient Boosted Trees for the Development of Disease Binary Classifiers

The ALS-disease binary classifier and FTD-disease binary classifier were developed using
Gradient Boosting Classifier, a machine learning algorithm that uses a gradient boosting
framework.
Diagnostic models were developed, validated and reported according to the TRIPOD guidelines
(Collins *et al.*, 2015) (https://www.tripod-statement.org/). Gradient Boosting trees (Elith *et al*,
2008; Witten *et al*, 2017), a decision-tree-based ensemble model, differ fundamentally from
conventional statistical techniques that aim to fit a single model using the entire dataset. Such
ensemble approach improves performance by combining strengths of models that learn the data
by recursive binary splits, such as trees, and of "boosting", an adaptive method for combining
several simple (base) models. At each iteration of the gradient boosting algorithm, a subsample
of the training data is selected at random (without replacement) from the entire training data set,
and then a simple base learner is fitted on each subsample. The final boosted trees model is an
additive tree model, constructed by sequentially fitting such base learners on different
subsamples. This procedure incorporates randomization, which is known to substantially
improve the predictor accuracy and also increase robustness. Additionally, boosted trees can fit
complex nonlinear relationships, and automatically handle interaction effects between predictors
as addition to other advantages of tree-based methods, such as handling features of different
types and accommodating missing data. Hence, in many cases their predictive performance is
superior to most traditional modelling methods.
382

Additional gain of these algorithms is the various loss functions that can be applied, both for
binary and multi-class problems. Using the softmax loss function, we explicitly estimated the

class conditional probabilities, which allow us to demonstrate the performance of each of the

classifiers both as "soft-classifiers" (i.e., predicting class probabilities) and "hard-classifiers" (i.e.,

setting a probability threshold and predicting a class). The former approximates a continuous

number as output - the class conditional probabilities - and then performs classification based

on these estimated probabilities. In contrast, hard classifiers output a discrete number as the

decision - directly targeting the classification decision boundary, without producing the

probability estimation.

A gradient boosting classifier was developed with a feature set of 132 miRNA predictors, age

and sex. Dataset was partitioned to training-set (75%) and validation-set (25%) which was used

as held-out data. The training-set was cross-validated during training with stratified 3-fold cross

validation. An ROC was generated for each of the folds and individual and mean AUCs were

calculated along with 95% confidence intervals.

The chosen hyperparams in ALS-disease classifier: gamma=0.1, learning_rate=0.1,

max_depth=3, n_estimators=120, subsample=0.9 and tol=0.01.

The chosen hyperparams in FTD-disease classifier: ccp_alpha=0.0, learning_rate=0.5,

max_depth=8, max_features=0.45, min_samples_leaf=14, min_samples_split=8,,

n_estimators=100, subsample=0.45 and tol=0.0001.

Gradient Boosted Trees for Multi-class Prediction with "one-vs-the-rest" Strategy

A Gradient Boosting multi-class classifier was implemented with "one-vs-all" (or one-vs-the-rest) strategy for diagnostic prediction between ALS diseased, FTD diseased and control subjects. Performance of a multi-class model is visualized by plotting the performance of 3 binary classifiers. "One-vs-rest" strategy involves fitting a single classifier per class, with the samples of that class considered as positive samples, and all other samples as negatives. A soft-classifier with "one-vs-rest" strategy outputs 3 probabilities for each subject in the data, where a good classifier should assign a high probability to the correct class, while assigning low probabilities to the other classes. Hyperparams for XGBClassifier: objective='multi:softprob', booster='gbtree', gamma=0.01, learning_rate=0.5, max_depth=3, n_estimators=120, subsample=0.9 and tol=0.01.

Dataset was partitioned to training-set (75%, stratified 3-fold cross validation) and validation-set (25%) which was used as held-out data. An ROC was generated for each of the folds and individual and mean AUCs were calculated along with 95% confidence intervals. The area under the ROC curve is a natural measure of separability between the 3 estimated probability distributions and possesses the singular merit that it is independent of costs, priors, or (consequently) any classification threshold(Hand & Till, 2001).

Predictor Selection by Recursive Feature Elimination (RFE)

For selecting the most predictive features during prediction model development, we used *Recursive Feature Elimination* (RFE) algorithm, an efficient recursive approach for eliminating features from a training dataset with K-fold cross validation. RFE works by iteratively removing features and using model accuracy to identify which features contribute the most to prediction. Tree-based importance scores of 132 miRNAs were used here in order to rank features, and thus reduce the dimension of miRNA measurements needed for prediction by ~90% (12-16 features in a model in total).

RFE was implemented with Extra Trees Classifier and the following hyperparms: criterion="entropy", max_features=0.9, n_estimators=10. The performance scorer used to optimize selection: ROC AUC score in single disease models and weighted ROC AUC score in the multi-disease model.

Feature Importance and SHAP Analysis

Although gradient boosting tree models are complex models, they can automatically provide an approximation of feature importance from the trained boosted trees. A miRNA predictor is assigned with an importance score in every single tree, where the Gini purity index is used to assess split points in the tree. The score of a feature is calculated based on the amount of improvement in the Gini index achieved by split points that include the feature, weighted by the number of observations in that node. The final importance score of a feature is calculated by an average across all decision trees within the final model.

For local interpretability of the predictive model, we used SHapley Additive exPlanations (SHAP) (Lundberg *et al.*, 2020), the current state of the art in Machine Learning explainability tools. Giving the smallest set of features that reduced the loss function the most (by XGBoost feature importance), SHAP provides estimates and visualizations to infer what decisions the model is making. This is achieved by quantifying the contribution that each feature brings to each prediction made by the model.

Appendix

IDs of 38 subjects removed due to age-based QC:

'CTRL_rep9', 'CTRL_rep10', 'CTRL_rep13', 'CTRL_rep19', 'CTRL_rep16',
'CTRL_rep18', 'CTRL_rep20', 'FTD30', 'CTRL_rep17', 'CTRL12', 'CTRL13',
'CTRL2', 'CTRL5', 'CTRL56', 'CTRL57', 'CTRL58', 'CTRL68', 'CTRL100',
'CTRL111', 'CTRL20', 'CTRL22', 'CTRL23', 'CTRL24', 'CTRL27', 'CTRL29',
'CTRL33', 'CTRL48', 'CTRL50', 'CTRL54', 'CTRL60', 'CTRL62', 'CTRL73',
'CTRL82', 'CTRL83', 'FA42', 'SA22', 'BUH00025', 'UCH00019'

Acknowledgments

We thank Vittoria Lombardi (UCL) for technical assistance. We acknowledge patients with FTD, ALS, MS and healthy volunteers for their contribution and ALS biomarkers study co-workers for biobanking, which has made this study possible (REC 09/H0703/27). We also thank the North Thames Local Research Network (LCRN) for its support. EH is the Mondry Family Professorial Chair and Head of the Nella and Leon Benoziyo Center for Neurological Diseases.

Funding

Research at the Hornstein laboratory is supported by the CReATe consortium and ALSA
(program: "Prognostic Value of miRNAs in Biofluids From ALS Patients"), the RADALA
Foundation; AFM Telethon (20576); the Weizmann–Brazil Center for Research on
Neurodegeneration at Weizmann Institute of Science; the Minerva Foundation, with funding
from the Federal German Ministry for Education and Research; the ISF Legacy Heritage Fund
(828/17); the Israel Science Foundation (135/16, 3497/21, 424/22, 425/22); United States -
Israel Binational Science Foundation (#2021181); A research grant from the Anita James Rosen
Foundation; Target ALS (118945); the Thierry Latran Foundation for ALS Research; the
European Research Council under the European Union's Seventh Framework Program
([FP7/2007–2013]/ERC grant agreement number 617351); ERA-Net for Research Programs on
Rare Diseases (eRARE FP7) via the Israel Ministry of Health; Dr Sydney Brenner and friends;
Edward and Janie Moravitz; A. Alfred Taubman through IsrALS; Yeda-Sela; Yeda-CEO; the
Israel Ministry of Trade and Industry; the Y. Leon Benoziyo Institute for Molecular Medicine; the
Nella and Leon Benoziyo Center for Neurological Disease; the Kekst Family Institute for Medical
Genetics; the David and Fela Shapell Family Center for Genetic Disorders Research; the Crown
Human Genome Center; the Nathan, Shirley, Philip, and Charlene Vener New Scientist Fund;
the Julius and Ray Charlestein Foundation; the Fraida Foundation; the Wolfson Family
Charitable Trust; the Adelis Foundation; Merck (UK); M. Halphen; the estates of F. Sherr, L.
Asseof, and L. Fulop; the Goldhirsh-Yellin Foundation; the Redhill Foundation–Sam and Jean
Rothberg Charitable Trust; Dr. Dvora and Haim Teitelbaum Endowment Fund; A research grant
from the Anita James Rosen Foundation. The ALS-Therapy Alliance, Motor Neuron Disease
Association (UK); this work was supported by the Motor Neuron Disease Association (MNDA)
839-791.

The Dementia Research Centre is supported by Alzheimer's Research UK, Brain Research
Trust, and The Wolfson Foundation. This work was supported by the NIHR Queen Square
Dementia Biomedical Research Unit, the NIHR UCL/H Biomedical Research Centre and the
Leonard Wolfson Experimental Neurology Centre (LWENC) Clinical Research Facility as well as
an Alzheimer's Society grant (AS-PG-16-007). JDR is supported by an MRC Clinician Scientist
Fellowship (MR/M008525/1) and has received funding from the NIHR Rare Disease
Translational Research Collaboration (BRC149/NS/MH). PF is supported by a Medical
Research Council Senior Clinical Fellowship, an MRC/MND LEW Fellowship, the NIHR UCLH
BRC and the Lady Edith Wolfson Fellowship scheme (MR/M008606/1 and MR/S006508/1).

NSY was supported by the Israeli Council for Higher Education (CHE) via the Weizmann Data

Science Research Center, by a research grant from the Estate of Tully and Michele Plesser and

by Maccabim Foundation. I.M. was supported by Teva Pharmaceutical Industries as part of the

Israeli National Network of Excellence in Neuroscience (fellowship no. 117941).

Authors' contribution

I.M., P.F., J.D.R. and E.H. conceived research.

I.M., N.S.Y. and E.H. analyzed the data.

A.M. and J.D.R. established cohort, gained ethical approval and collected human samples for

research.

Y.B., C.H. and I.S. assisted research.

I.M., N.S.Y., P.F., A.M., J.D.R. and E.H. wrote the manuscript, with comments and final

approval by all other authors.

J.D.W. provided resources for research and input in research development.

A.M. and J.D.R. are corresponding authors for cohorts and clinical data. P.F. and E.H. are

corresponding authors for all other facets of the work.

Conflicts of interests

The authors state that they have no conflicts of interests.

References

Abramzon YA, Fratta P, Traynor BJ, Chia R (2020) The Overlapping Genetics of Amyotrophic
Lateral Sclerosis and Frontotemporal Dementia. *Front Neurosci* 14: 42
Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment
and time. *Nat Rev Neurol* 9: 617-628
Al Shweiki MR, Steinacker P, Oeckl P, Hengerer B, Danek A, Fassbender K, Diehl-Schmid J,
Jahn H, Anderl-Straub S, Ludolph AC *et al* (2019) Neurofilament light chain as a blood
biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal
dementia. *J Psychiatr Res* 113: 137-140
Allach El Khattabi L, Heide S, Caberg J-H, Andrieux J, Doco Fenzy M, Vincent-Delorme C,
Callier P, Chantot-Bastaraud S, Afenjar A, Boute-Benejean O *et al* (2020) 16p13.11
microduplication in 45 new patients: refined clinical significance and genotype–phenotype
correlations. *Journal of Medical Genetics* 57: 301-307
Andersen PM, Al-Chalabi A (2011) Clinical genetics of amyotrophic lateral sclerosis: what do we
really know? *Nat Rev Neurol* 7: 603-615
Ashton NJ, Janelidze S, Al Khleifat A, Leuzy A, van der Ende EL, Karikari TK, Benedet AL,
Pascoal TA, Lleo A, Parnetti L *et al* (2021) A multicentre validation study of the diagnostic value
of plasma neurofilament light. *Nat Commun* 12: 3400
Azencott C-A, 2020. Machine learning tools for biomarker discovery. Sorbonne Université ,
UPMC.
Banack SA, Dunlop RA, Cox PA (2020) An miRNA fingerprint using neural-enriched
extracellular vesicles from blood plasma: towards a biomarker for amyotrophic lateral
sclerosis/motor neuron disease. *Open Biol* 10: 200116
Baulina N, Kulakova O, Kiselev I, Osmak G, Popova E, Boyko A, Favorova O (2018) Immune-
related miRNA expression patterns in peripheral blood mononuclear cells differ in multiple
sclerosis relapse and remission. *J Neuroimmunol* 317: 67-76
Bellini S, Saraceno C, Benussi L, Squitti R, Cimini S, Ricci M, Canafoglia L, Coppola C, Puoti G,
Ferrari C *et al* (2022) Plasma Small Extracellular Vesicles with Complement Alterations in
GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration. *Cells* 11
Benigni M, Ricci C, Jones AR, Giannini F, Al-Chalabi A, Battistini S (2016) Identification of
miRNAs as potential biomarkers in cerebrospinal fluid from amyotrophic lateral sclerosis
patients. *Neuromolecular medicine* 18: 551-560
Benussi A, Gazzina S, Premi E, Cosseddu M, Archetti S, Dell'Era V, Cantoni V, Cotelli MS,
Alberici A, Micheli A *et al* (2019) Clinical and biomarker changes in presymptomatic genetic
frontotemporal dementia. *Neurobiol Aging* 76: 133-140
Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark
CM, Rosso S *et al* (2008) CSF biomarkers in frontotemporal lobar degeneration with known
pathology. *Neurology* 70: 1827-1835
Borroni B, Benussi A, Archetti S, Galimberti D, Parnetti L, Nacmias B, Sorbi S, Scarpini E,
Padovani A (2015) Csf p-tau181/tau ratio as biomarker for TDP pathology in frontotemporal
dementia. *Amyotroph Lateral Scler Frontotemporal Degener* 16: 86-91
Bourbouli M, Rentzos M, Bougea A, Zouvelou V, Constantinides VC, Zaganas I, Evdokimidis I,
Kapaki E, Paraskevas GP (2017) Cerebrospinal Fluid TAR DNA-Binding Protein 43 Combined
with Tau Proteins as a Candidate Biomarker for Amyotrophic Lateral Sclerosis and
Frontotemporal Dementia Spectrum Disorders. *Dement Geriatr Cogn Disord* 44: 144-152
Bright F, Werry EL, Dobson-Stone C, Piguet O, Ittner LM, Halliday GM, Hodges JR, Kiernan
MC, Loy CT, Kassiou M *et al* (2019) Neuroinflammation in frontotemporal dementia. *Nature*
Reviews Neurology 15: 540-555

Bu X, Li D, Wang F, Sun Q, Zhang Z (2020) Protective Role of Astrocyte-Derived Exosomal
microRNA-361 in Cerebral Ischemic-Reperfusion Injury by Regulating the AMPK/mTOR
Signaling Pathway and Targeting CTSB. *Neuropsychiatr Dis Treat* 16: 1863-1877
Chang WS, Wang YH, Zhu XT, Wu CJ (2017) Genome-Wide Profiling of miRNA and mRNA
Expression in Alzheimer's Disease. *Med Sci Monit* 23: 2721-2731
Chen Q, Xu J, Li L, Li H, Mao S, Zhang F, Zen K, Zhang CY, Zhang Q (2014) MicroRNA-23a/b
and microRNA-27a/b suppress Apaf-1 protein and alleviate hypoxia-induced neuronal
apoptosis. *Cell Death Dis* 5: e1132
Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update.
Mol Neurodegener 8: 28
Chouliaras L, Thomas A, Malpetti M, Donaghy P, Kane J, Mak E, Savulich G, Prats-Sedano
MA, Heslegrave AJ, Zetterberg H *et al* (2022) Differential levels of plasma biomarkers of
neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and
progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* 93: 651-658
Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, Couthouis J, Lu YF,
Wang Q, Krueger BJ *et al* (2015) Exome sequencing in amyotrophic lateral sclerosis identifies
risk genes and pathways. *Science* 347: 1436-1441
Cloutier F, Marrero A, O'Connell C (2015) MicroRNAs as potential circulating biomarkers for
amyotrophic lateral sclerosis. *Journal of Molecular Neuroscience* 56: 102-112
Coenen-Stass AML, Magen I, Brooks T, Ben-Dov IZ, Greensmith L, Hornstein E, Fratta P
(2018) Evaluation of methodologies for microRNA biomarker detection by next generation
sequencing. *RNA Biol* 15: 1133-1145
Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown
D, Chen C *et al* (2008) Identification of miRNA changes in Alzheimer's disease brain and CSF
yields putative biomarkers and insights into disease pathways. *J Alzheimers Dis* 14: 27-41
Collaborators GBDMND (2018) Global, regional, and national burden of motor neuron diseases
1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*
17: 1083-1097
Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent Reporting of a multivariable
prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann*
Intern Med 162: 55-63
Conforti FL, Renton AE, Houlden H (2021) Editorial: Multifaceted Genes in Amyotrophic Lateral
Sclerosis-Frontotemporal Dementia. *Front Neurosci* 15: 680185
Das S, Dewit N, Jacobs D, Pijnenburg YAL, In 't Veld S, Coppens S, Quaglia M, Hirtz C,
Teunissen CE, Vanmechelen E (2022) A Novel Neurofilament Light Chain ELISA Validated in
Patients with Alzheimer's Disease, Frontotemporal Dementia, and Subjective Cognitive Decline,
and the Evaluation of Candidate Proteins for Immunoassay Calibration. *Int J Mol Sci* 23
de Andrade HM, de Albuquerque M, Avansini SH, de SRC, Dogini DB, Nucci A, Carvalho B,
Lopes-Cendes I, Franca MC, Jr. (2016) MicroRNAs-424 and 206 are potential prognostic
markers in spinal onset amyotrophic lateral sclerosis. *J Neurol Sci* 368: 19-24
Delaby C, Alcolea D, Carmona-Iragui M, Illan-Gala I, Morenas-Rodriguez E, Barroeta I, Altuna
M, Estelles T, Santos-Santos M, Turon-Sans J *et al* (2020) Differential levels of Neurofilament
Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders.
Sci Rep 10: 9161
Denk J, Oberhauser F, Kornhuber J, Wiltfang J, Fassbender K, Schroeter ML, Volk AE, Diehl-
Schmid J, Prudlo J, Danek A *et al* (2018) Specific serum and CSF microRNA profiles distinguish
sporadic behavioural variant of frontotemporal dementia compared with Alzheimer patients and
cognitively healthy controls. *PLoS One* 13: e0197329
Dolati S, Aghebati-Maleki L, Ahmadi M, Marofi F, Babaloo Z, Ayramloo H, Jafarisavari Z,
Oskouei H, Afkham A, Younesi V *et al* (2018) Nanocurcumin restores aberrant miRNA

expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial. *J Cell Physiol* 233: 5222-5230

Eitan C, Hornstein E (2016) Vulnerability of microRNA biogenesis in FTD-ALS. *Brain Res*

Elith J, Leathwick JR, Hastie T (2008) A working guide to boosted regression trees. *J Anim Ecol* 77: 802-813

Emde A, Eitan C, Liou LL, Libby RT, Rivkin N, Magen I, Reichenstein I, Oppenheim H, Eilam R, Silvestroni A *et al* (2015) Dysregulated miRNA biogenesis downstream of cellular stress and ALS-causing mutations: a new mechanism for ALS. *EMBO J* 34: 2633-2651

Eratne D, Loi SM, Li QX, Stehmann C, Malpas CB, Santillo A, Janelidze S, Cadwallader C, Walia N, Ney B *et al* (2022) Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. *Alzheimers Dement*

Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR (2018) Towards a TDP-43-Based Biomarker for ALS and FTLD. *Mol Neurobiol* 55: 7789-7801

Forgrave LM, Ma M, Best JR, DeMarco ML (2019) The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: A systematic review and meta-analysis. *Alzheimers Dement (Amst)* 11: 730-743

Goncalves M, De Carvalho M, Peixoto C, Alves P, Barreto C, Oliva A, Pinto S, Laborinho-Pronto A, Gromicho M, Costa J (2017) Phosphoneurofilament heavy chain and vascular endothelial growth factor as cerebrospinal fluid biomarkers for ALS. *Amyotroph Lateral Scler Frontotemporal Degener* 18: 134-136

Goncalves TF, Piergiorge RM, Dos Santos JM, Gusmao J, Pimentel MMG, Santos-Reboucas CB (2019) Network Profiling of Brain-Expressed X-Chromosomal MicroRNA Genes Implicates Shared Key MicroRNAs in Intellectual Disability. *J Mol Neurosci* 67: 295-304

Gonzalez-Garza MT, Martinez HR, Cruz-Vega DE, Hernandez-Torre M, Moreno-Cuevas JE (2018) Adipsin, MIP-1b, and IL-8 as CSF Biomarker Panels for ALS Diagnosis. *Dis Markers* 2018: 3023826

Grasso M, Piscopo P, Talarico G, Ricci L, Crestini A, Tosto G, Gasparini M, Bruno G, Denti MA, Confaloni A (2019) Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects. *Neurobiol Aging*

Hand DJ, Till RJ (2001) A simple generalisation of the area under the ROC curve for multiple class classification problems. *Machine learning* 45: 171-186

Hansson O, Santillo AF, Meeter LH, Nilsson K, Landqvist Waldo M, Nilsson C, Blennow K, van Swieten JC, Janelidze S (2019) CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. *Ann Clin Transl Neurol* 6: 863-872

Haramati S, Chapnik E, Sztainberg Y, Eilam R, Zwang R, Gershoni N, McGlinn E, Heiser PW, Wills AM, Wirguin I *et al* (2010) miRNA malfunction causes spinal motor neuron disease. *Proc Natl Acad Sci U S A* 107: 13111-13116

Hardiman O, van den Berg LH, Kiernan MC (2011) Clinical diagnosis and management of amyotrophic lateral sclerosis. *Nat Rev Neurol* 7: 639-649

He B, Chen W, Zeng J, Tong W, Zheng P (2020) MicroRNA-326 decreases tau phosphorylation and neuron apoptosis through inhibition of the JNK signaling pathway by targeting VAV1 in Alzheimer's disease. *J Cell Physiol* 235: 480-493

Honardoost MA, Kiani-Esfahani A, Ghaedi K, Etemadifar M, Salehi M (2014) miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis. *Gene* 544: 128-133

Hu WT, Watts K, Grossman M, Glass J, Lah JJ, Hales C, Shelnutt M, Van Deerlin V, Trojanowski JQ, Levey AI (2013) Reduced CSF p-Tau181 to Tau ratio is a biomarker for FTLD-TDP. *Neurology* 81: 1945-1952

Jiskoot LC, Panman JL, Meeter LH, Dopper EGP, Donker Kaat L, Franzen S, van der Ende EL,
van Minkelen R, Rombouts S, Papma JM *et al* (2019) Longitudinal multimodal MRI as
prognostic and diagnostic biomarker in presymptomatic familial frontotemporal dementia. *Brain*
142: 193-208
Joilin G, Leigh PN, Newbury SF, Hafezparast M (2019) An overview of microRNAs as
biomarkers of ALS. *Frontiers in neurology* 10: 186
Katisko K, Cajanus A, Huber N, Jaaskelainen O, Kokkola T, Karkkainen V, Rostalski H,
Hartikainen P, Koivisto AM, Hannonen S *et al* (2021) GFAP as a biomarker in frontotemporal
dementia and primary psychiatric disorders: diagnostic and prognostic performance. *J Neurol*
Neurosurg Psychiatry 92: 1305-1312
Katisko K, Cajanus A, Jaaskelainen O, Kontkanen A, Hartikainen P, Korhonen VE, Helisalmi S,
Haapasalo A, Koivumaa-Honkanen H, Herukka SK *et al* (2020) Serum neurofilament light chain
is a discriminative biomarker between frontotemporal lobar degeneration and primary
psychiatric disorders. *J Neurol* 267: 162-167
Kmetzsch V, Anquetil V, Saracino D, Rinaldi D, Camuzat A, Gareau T, Jornea L, Forlani S,
Couratier P, Wallon D (2021) Plasma microRNA signature in presymptomatic and symptomatic
subjects with C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis.
Journal of Neurology, Neurosurgery & Psychiatry 92: 485-493
Kohen R, Barlev J, Hornung G, Stelzer G, Feldmesser E, Kogan K, Safran M, Leshkowitz D
(2019) UTAP: User-friendly Transcriptome Analysis Pipeline. *BMC bioinformatics* 24: 154
Kozomara A, Griffiths-Jones S (2014) miRBase: annotating high confidence microRNAs using
deep sequencing data. *Nucleic Acids Res* 42: D68-73
Krishnan G, Raitcheva D, Bartlett D, Prudencio M, McKenna-Yasek DM, Douthwright C,
Oskarsson BE, Ladha S, King OD, Barmada SJ *et al* (2022) Poly(GR) and poly(GA) in
cerebrospinal fluid as potential biomarkers for C9ORF72-ALS/FTD. *Nat Commun* 13: 2799
Lindberg RL, Hoffmann F, Mehling M, Kuhle J, Kappos L (2010) Altered expression of miR-17-
5p in CD4+ lymphocytes of relapsing-remitting multiple sclerosis patients. *Eur J Immunol* 40:
888-898
Ling SC, Polymenidou M, Cleveland DW (2013) Converging mechanisms in ALS and FTD:
disrupted RNA and protein homeostasis. *Neuron* 79: 416-438
Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for
RNA-seq data with DESeq2. *Genome Biol* 15: 550
Ludwig N, Fehlmann T, Kern F, Gogol M, Maetzler W, Deutscher S, Gurlit S, Schulte C, von
Thaler AK, Deuschle C *et al* (2019) Machine Learning to Detect Alzheimer's Disease from
Circulating Non-coding RNAs. *Genomics Proteomics Bioinformatics* 17: 430-440
Ludwig N, Leidinger P, Becker K, Backes C, Fehlmann T, Pallasch C, Rheinheimer S, Meder B,
Stähler C, Meese E *et al* (2016) Distribution of miRNA expression across human tissues.
Nucleic Acids Research 44: 3865-3877
Lundberg SM, Erion G, Chen H, DeGrave A, Prutkin JM, Nair B, Katz R, Himmelfarb J, Bansal
N, Lee S-I (2020) From local explanations to global understanding with explainable AI for trees.
Nature Machine Intelligence 2: 56-67
Magen I, Aharoni S, Yacovzada NS, Tokatly Latzer I, Alves CRR, Sagi L, Fattal-Valevski A,
Swoboda KJ, Katz J, Bruckheimer E *et al* (2022) Muscle microRNAs in the cerebrospinal fluid
predict clinical response to nusinersen therapy in type II and type III spinal muscular atrophy
patients. *Eur J Neurol* 29: 2420-2430
Magen I, Yacovzada NS, Yanowski E, Coenen-Stass A, Grosskreutz J, Lu CH, Greensmith L,
Malaspina A, Fratta P, Hornstein E (2021) Circulating miR-181 is a prognostic biomarker for
amyotrophic lateral sclerosis. *Nat Neurosci* 24: 1534-1541
Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, Chio A, Restagno G,
Nicolaou N, Simon-Sanchez J *et al* (2012) Frequency of the C9orf72 hexanucleotide repeat

expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-
sectional study. *Lancet Neurol* 11: 323-330
Malacarne C, Galbiati M, Giagnorio E, Cavalcante P, Salerno F, Andreetta F, Cagnoli C, Taiana
M, Nizzardo M, Corti S *et al* (2021) Dysregulation of Muscle-Specific MicroRNAs as Common
Pathogenic Feature Associated with Muscle Atrophy in ALS, SMA and SBMA: Evidence from
Animal Models and Human Patients. *Int J Mol Sci* 22
McCarthy J, Collins DL, Ducharme S (2018) Morphometric MRI as a diagnostic biomarker of
frontotemporal dementia: A systematic review to determine clinical applicability. *Neuroimage*
Clin 20: 685-696
McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ, Work Group on
Frontotemporal D, Pick's D (2001) Clinical and pathological diagnosis of frontotemporal
dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. *Arch*
Neurol 58: 1803-1809
Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC (2017) Imaging and fluid biomarkers in
frontotemporal dementia. *Nature Reviews Neurology* 13: 406
Meeter LHH, Vijverberg EG, Del Campo M, Rozemuller AJM, Donker Kaat L, de Jong FJ, van
der Flier WM, Teunissen CE, van Swieten JC, Pijnenburg YAL (2018) Clinical value of
neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. *Neurology*
90: e1231-e1239
Muller M, Kuiperij HB, Claassen JA, Kusters B, Verbeek MM (2014) MicroRNAs in Alzheimer's
disease: differential expression in hippocampus and cell-free cerebrospinal fluid. *Neurobiol*
Aging 35: 152-158
Muller M, Kuiperij HB, Versleijen AA, Chiasserini D, Farotti L, Baschieri F, Parnetti L, Struyfs H,
De Roeck N, Luyckx J *et al* (2016) Validation of microRNAs in Cerebrospinal Fluid as
Biomarkers for Different Forms of Dementia in a Multicenter Study. *J Alzheimers Dis* 52: 1321-
1333
Nelson PT, Wang WX (2010) MiR-107 is reduced in Alzheimer's disease brain neocortex:
validation study. *J Alzheimers Dis* 21: 75-79
Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T,
Grossman M, Clark CM *et al* (2006) Ubiquitinated TDP-43 in frontotemporal lobar degeneration
and amyotrophic lateral sclerosis. *Science* 314: 130-133
Ni J, Wang X, Chen S, Liu H, Wang Y, Xu X, Cheng J, Jia J, Zhen X (2015) MicroRNA let-7c-5p
protects against cerebral ischemia injury via mechanisms involving the inhibition of microglia
activation. *Brain Behav Immun* 49: 75-85
Niikado M, Chrem-Mendez P, Itzcovich T, Barbieri-Kennedy M, Calandri I, Martinetto H, Serra
M, Calvar J, Campos J, Russo MJ *et al* (2019) Evaluation of Cerebrospinal Fluid Neurofilament
Light Chain as a Routine Biomarker in a Memory Clinic. *J Gerontol A Biol Sci Med Sci* 74: 442-
445
Niwald M, Migdalska-Sek M, Brzezianska-Lasota E, Miller E (2017) Evaluation of Selected
MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to
Cognition, Depression, and Disability. *J Mol Neurosci* 63: 275-282
Oeckl P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, Diehl-Schmid J, Grimmer T,
Halbgebauer S, Kort AM, Lima M, Marques TM *et al* (2022) Serum GFAP differentiates
Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. *J*
Neurol Neurosurg Psychiatry
Peters OM, Ghasemi M, Brown RH, Jr. (2015) Emerging mechanisms of molecular pathology in
ALS. *J Clin Invest* 125: 1767-1779
Piscopo P, Grasso M, Puopolo M, D'Acunto E, Talarico G, Crestini A, Gasparini M, Campopiano
R, Gambardella S, Castellano AE *et al* (2018) Circulating miR-127-3p as a Potential Biomarker
for Differential Diagnosis in Frontotemporal Dementia. *J Alzheimers Dis* 65: 455-464

Prado LGR, Rocha NP, de Souza LC, Bicalho ICS, Gomez RS, Vidigal-Lopes M, Braz NFT,
Vieira ELM, Teixeira AL (2018) Longitudinal assessment of clinical and inflammatory markers in
patients with amyotrophic lateral sclerosis. *J Neurol Sci* 394: 69-74
Prendecki M, Florczak-Wyspianska J, Kowalska M, Ilkowski J, Grzelak T, Bialas K, Kozubski W,
Dorszewska J (2019) APOE genetic variants and apoE, miR-107 and miR-650 levels in
Alzheimer's disease. *Folia Neuropathol* 57: 106-116
Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A, Diaz-Cruz C,
Gholipour T, Glanz BI *et al* (2018) Correlating serum micrornas and clinical parameters in
amyotrophic lateral sclerosis. *Muscle Nerve* 58: 261-269
Ravnik-Glavač M, Glavač D (2020) Circulating RNAs as potential biomarkers in amyotrophic
lateral sclerosis. *International journal of molecular sciences* 21: 1714
Regev K, Healy BC, Khalid F, Paul A, Chu R, Tauhid S, Tummala S, Diaz-Cruz C, Raheja R,
Mazzola MA *et al* (2017) Association Between Serum MicroRNAs and Magnetic Resonance
Imaging Measures of Multiple Sclerosis Severity. *JAMA Neurol* 74: 275-285
Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisakk P, Chitnis
T, Jagodic M *et al* (2018) Identification of MS-specific serum miRNAs in an international
multicenter study. *Neurol Neuroimmunol Neuroinflamm* 5: e491
Reichenstein I, Eitan C, Diaz-Garcia S, Haim G, Magen I, Siany A, Hoye ML, Rivkin N, Olender
T, Toth B *et al* (2019) Human genetics and neuropathology suggest a link between miR-218 and
amyotrophic lateral sclerosis pathophysiology. *Science Translational Medicine* 11: eaav5264
Renton AE, Majounie E, Waite A, Simon-Sanchez J, Rollinson S, Gibbs JR, Schymick JC,
Laaksovirta H, van Swieten JC, Myllykangas L *et al* (2011) A hexanucleotide repeat expansion
in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72: 257-268
Ricci C, Marzocchi C, Battistini S (2018) MicroRNAs as biomarkers in amyotrophic lateral
sclerosis. *Cells* 7: 219
Robberecht W, Philips T (2013) The changing scene of amyotrophic lateral sclerosis. *Nat Rev*
Neurosci 14: 248-264
Rossi D, Volanti P, Brambilla L, Colletti T, Spataro R, La Bella V (2018) CSF neurofilament
proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. *J Neurol*
265: 510-521
Saucier D, Wajnberg G, Roy J, Beauregard AP, Chacko S, Crapoulet N, Fournier S, Ghosh A,
Lewis SM, Marrero A *et al* (2019) Identification of a circulating miRNA signature in extracellular
vesicles collected from amyotrophic lateral sclerosis patients. *Brain Res* 1708: 100-108
Schneider R, McKeever P, Kim T, Graff C, van Swieten JC, Karydas A, Boxer A, Rosen H,
Miller BL, Laforce R, Jr. *et al* (2018) Downregulation of exosomal miR-204-5p and miR-632 as a
biomarker for FTD: a GENFI study. *J Neurol Neurosurg Psychiatry* 89: 851-858
Sharaf-Eldin WE, Kishk NA, Gad YZ, Hassan H, Ali MAM, Zaki MS, Mohamed MR, Essawi ML
(2017) Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential
diagnosis of immune-mediated neuroinflammatory diseases. *J Neurol Sci* 383: 188-198
Sheikh-Bahaei N, Sajjadi SA, Pierce AL (2017) Current role for biomarkers in clinical diagnosis
of Alzheimer disease and frontotemporal dementia. *Current treatment options in neurology* 19:
46
Sheinerman KS, Toledo JB, Tsivinsky VG, Irwin D, Grossman M, Weintraub D, Hurtig HI, Chen-
Plotkin A, Wolk DA, McCluskey LF *et al* (2017) Circulating brain-enriched microRNAs as novel
biomarkers for detection and differentiation of neurodegenerative diseases. *Alzheimers Res*
Ther 9: 89
Silva-Spinola A, Lima M, Leitao MJ, Duraes J, Tabuas-Pereira M, Almeida MR, Santana I,
Baldeiras I (2022) Serum neurofilament light chain as a surrogate of cognitive decline in
sporadic and familial frontotemporal dementia. *Eur J Neurol* 29: 36-46
Snowden JS, Neary D, Mann DM (2002) Frontotemporal dementia. *Br J Psychiatry* 180: 140-
143

Sproviero D, Gagliardi S, Zucca S, Arigoni M, Giannini M, Garofalo M, Olivero M, Dell'Orco M,
Pansarasa O, Bernuzzi S *et al* (2021) Different miRNA Profiles in Plasma Derived Small and
Large Extracellular Vesicles from Patients with Neurodegenerative Diseases. *Int J Mol Sci* 22
Strong MJ, Abrahams S, Goldstein LH, Woolley S, McLaughlin P, Snowden J, Mioshi E,
Roberts-South A, Benatar M, HortobaGyi T *et al* (2017) Amyotrophic lateral sclerosis -
frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotroph Lateral*
Scler Frontotemporal Degener 18: 153-174
Sun L, Liu A, Zhang J, Ji W, Li Y, Yang X, Wu Z, Guo J (2018) miR-23b improves cognitive
impairments in traumatic brain injury by targeting ATG12-mediated neuronal autophagy. *Behav*
Brain Res 340: 126-136
Takahashi I, Hama Y, Matsushima M, Hirotani M, Kano T, Hohzen H, Yabe I, Utsumi J, Sasaki
H (2015) Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral
Sclerosis. *Mol Brain* 8: 67
Tan YJ, Wong BYX, Vaidyanathan R, Sreejith S, Chia SY, Kandiah N, Ng ASL, Zeng L (2021)
Altered Cerebrospinal Fluid Exosomal microRNA Levels in Young-Onset Alzheimer's Disease
and Frontotemporal Dementia. *J Alzheimers Dis Rep* 5: 805-813
Tasca E, Pegoraro V, Merico A, Angelini C (2016) Circulating microRNAs as biomarkers of
muscle differentiation and atrophy in ALS. *Clin Neuropathol* 35: 22-30
Teunissen CE, Elias N, Koel-Simmelink MJ, Durieux-Lu S, Malekzadeh A, Pham TV, Piersma
SR, Beccari T, Meeter LH, Dopper EG *et al* (2016) Novel diagnostic cerebrospinal fluid
biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics.
Alzheimers Dement (Amst) 2: 86-94
Thijssen EH, Verberk IMW, Kindermans J, Abramian A, Vanbrabant J, Ball AJ, Pijnenburg Y,
Lemstra AW, van der Flier WM, Stoops E *et al* (2022) Differential diagnostic performance of a
panel of plasma biomarkers for different types of dementia. *Alzheimers Dement (Amst)* 14:
e12285
Toivonen JM, Manzano R, Olivan S, Zaragoza P, Garcia-Redondo A, Osta R (2014) MicroRNA-
206: a potential circulating biomarker candidate for amyotrophic lateral sclerosis. *PLoS One* 9:
e89065
Turner MR, Kiernan MC, Leigh PN, Talbot K (2009) Biomarkers in amyotrophic lateral sclerosis.
The Lancet Neurology 8: 94-109
van der Ende EL, Xiao M, Xu D, Poos JM, Panman JL, Jiskoot LC, Meeter LH, Dopper EG,
Papma JM, Heller C *et al* (2020) Neuronal pentraxin 2: a synapse-derived CSF biomarker in
genetic frontotemporal dementia. *J Neurol Neurosurg Psychiatry* 91: 612-621
van Es MA, Hardiman O, Chio A, Al-Chalabi A, Pasterkamp RJ, Veldink JH, van den Berg LH
(2017) Amyotrophic lateral sclerosis. *Lancet* 390: 2084-2098
Verde F, Otto M, Silani V (2021) Neurofilament Light Chain as Biomarker for Amyotrophic
Lateral Sclerosis and Frontotemporal Dementia. *Front Neurosci* 15: 679199
Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, Kazoka M, Wollff H,
Heath PR, Shaw PJ (2017a) Serum miRNAs miR-206, 143-3p and 374b-5p as potential
biomarkers for amyotrophic lateral sclerosis (ALS). *Neurobiology of aging* 55: 123-131
Waller R, Goodall EF, Milo M, Cooper-Knock J, Da Costa M, Hobson E, Kazoka M, Wollff H,
Heath PR, Shaw PJ *et al* (2017b) Serum miRNAs miR-206, 143-3p and 374b-5p as potential
biomarkers for amyotrophic lateral sclerosis (ALS). *Neurobiol Aging* 55: 123-131
Wang J, Chen C, Zhang Y (2020) An investigation of microRNA-103 and microRNA-107 as
potential blood-based biomarkers for disease risk and progression of Alzheimer's disease. *J Clin*
Lab Anal 34: e23006
Wang L, Zhang L (2020) Circulating microRNAs as diagnostic biomarkers for motor neuron
disease. *Frontiers in neuroscience* 14
Wang WX, Rajeev BW, Stromberg AJ, Ren N, Tang G, Huang Q, Rigoutsos I, Nelson PT (2008)
The expression of microRNA miR-107 decreases early in Alzheimer's disease and may

accelerate disease progression through regulation of beta-site amyloid precursor protein-
cleaving enzyme 1. *J Neurosci* 28: 1213-1223
Wilson KM, Katona E, Glaria I, Carcole M, Swift IJ, Sogorb-Esteve A, Heller C, Bouzigues A,
Heslegrave AJ, Keshavan A *et al* (2022) Development of a sensitive trial-ready poly(GP) CSF
biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral
sclerosis. *J Neurol Neurosurg Psychiatry* 93: 761-771
Wingo TS, Yang J, Fan W, Min Canon S, Gerasimov ES, Lori A, Logsdon B, Yao B, Seyfried
NT, Lah JJ *et al* (2020) Brain microRNAs associated with late-life depressive symptoms are also
associated with cognitive trajectory and dementia. *NPJ Genom Med* 5: 6
Witten IH, Frank E, Hall MA, Pal CJ (2017) Ensemble Learning. In: *Data Mining (Fourth Edition)*,
Witten I.H., Frank E., Hall M.A., Pal C.J. (eds.) pp. 479-501. Morgan Kaufmann:
Xu Z, Henderson RD, David M, McCombe PA (2016) Neurofilaments as Biomarkers for
Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. *PLoS One* 11:
e0164625
Yang D, Wang WZ, Zhang XM, Yue H, Li B, Lin L, Fu J (2014) MicroRNA expression aberration
in Chinese patients with relapsing remitting multiple sclerosis. *J Mol Neurosci* 52: 131-137
Yilmaz SG, Erdal ME, Ozge AA, Sungur MA (2016) Can Peripheral MicroRNA Expression Data
Serve as Epigenomic (Upstream) Biomarkers of Alzheimer's Disease? *OMICS* 20: 456-461
Zhao XH, Wang YB, Yang J, Liu HQ, Wang LL (2019) MicroRNA-326 suppresses iNOS
expression and promotes autophagy of dopaminergic neurons through the JNK signaling by
targeting XBP1 in a mouse model of Parkinson's disease. *J Cell Biochem* 120: 14995-15006
898

Main tables and Figures

	Control	ALS	Control	FTD
Number of subjects (% males)	102 (28%)	206 (59%)	56 (46%)	169 (65%)
Age at enrolment	49.9±13.7 yr.	64.4±11.0 yr.	61.0±13.3 yr.	65.6±8.4 yr.
Age of onset (1st reported symptoms)		62.1±11.3 yr.		60.1±8.4 yr.
Disease duration at enrolment		28.2±30.7 m		67.0±41.4 m
ALSFRS-R at enrolment		36.0±8.1		
El-Escorial (Definite/probable/lab-supported/possible/suspected/other)		57/90/27/29/1/2		
Bulbar onset/total		64/206		
Riluzole treated / total		139/206		
ALS Family history / total		9/206		
C9ORF72 genetics/total		14/206		
FTD clinical subtype (bvFTD/PNFA/SD/FTD-ALS/others)				82/40/28/5/14
FTD Mutation carriers (C9ORF72/MAPT/ GRN/TBK1)				18/14/13/2
Likely FTD pathology (TDP-43/Tau)				63/19

Table 1. Summary of demographic and clinical characteristics of ALS and FTD cases and their respective control samples. ALSFRS-R: ALS functional rating scale. bvFTD: behavioural FTD; PNFA: progressive nonfluent aphasia; SD: semantic dementia. Mean±SD.

Class/ Metric	Precision/ PPV	Sensitivity/ Recall	Specificity/ TNR	NPV	f1	# samples
Controls	66%	50%	88%	80%	57%	38
FTD	90%	92%	95%	96%	91%	39
ALS	71%	83%	79%	88%	76%	47
macro avg	75%	75%			75%	124
weighted avg	75%	76%			75%	124

908
909   ***Table 2.*** *Performance summary of "one-vs-rest" multi-disease classifier*
910
911
912

913
914 ***Figure 1.* miRNA signature associated with ALS and FTD**. MA plot of differential miRNA expression in
915 (A) ALS patients (N=202) versus non-neurodegenerative controls (N=125); (B) FTD patients (N=168)
916 versus non-neurodegenerative controls (N=125); (C) FTD versus ALS. Log 2 transformed fold change (y-
917 axis), against mean miRNA abundance (x-axis). Red: significantly changed miRNAs (p<0.05, Wald test).

918
919
920

Figure 2: Diagnosis of FTD by a distinctive cell free miRNA signature.

921
922   (A) Accuracy (AUC ROC, y-axis) as a function of the number of plasma miRNAs used in the FTD
923   prediction model. Increasing numbers of miRNA features (x-axis) successively-elected in the
924   recursive feature elimination process reveal an optimum at 13 features (blue line).
925   (B) ROC curves in the training set: true positive rate (y-axis) vs. false positive rate (x-axis). Mean
926   values and variance when data from 219 samples with 3-fold cross validation. Mean AUC 0.93 ±
927   SD. 95% CI is 91%-95%.
928   (C) Performance and generalizability on held-out data revealed by a ROC curve with AUC of 0.9 and
929   average precision of 0.89.
930   (D) Reliability diagram, plotting truly observed vs. predicted average probability in five bins reveals a
931   sufficient calibrated model on the held-out set.
932   (E) Confusion matrix showing the prediction errors on held out dataset. At a probability threshold of
933   60%, and 0.83 Negative predictive value (NPV), over 0.85 True Positive Rate (also, recall/
934   sensitivity) and 0.17 False Positive Rate. Specificity is 0.87 and 0.2 false discovery rate.
935   (F) AUC ROC of a model trained with only a subset of top 13 most predictive features, reveals a
936   stable performance with the selected final features.

938
939 *Figure 3: The contribution of individual miRNAs to the predictor of FTD diagnosis.*
940 (A) Mean absolute SHapley Additive exPlanations (SHAP) values break down the impact of specific
941 miRNAs on FTD disease predictor output in the held-out cohort. (B) Illustration of the relationship
942 between the miRNA levels (low - blue to high - red), SHAP values and the impact on the prediction in the
943 held-out cohort

944
Figure 4: Diagnosis of ALS by a distinctive cell free miRNA signature.
(A) Accuracy (AUC ROC, y-axis) as a function of the number of plasma miRNAs used in the ALS
prediction model. Increasing numbers of miRNA features (x-axis) successively elected in the
recursive feature elimination process reveal an optimum at 12 features (blue line).
(B) ROC curves in the training set: true positive rate (y-axis) vs. false positive rate (x-axis). Mean
values and variance when data from 245 samples with 3-fold cross validation. Mean AUC 0.86 ±
SD. 95% CI is 82%-90%.
(C) Performance and generalizability on held-out data revealed by a ROC curve with AUC of 0.78
and average precision of 0.82.
(D) Reliability diagram, plotting truly observed vs. predicted average probability in five bins reveals a
calibrated model on the held-out set.
(E) Confusion matrix showing the prediction errors on held out dataset. At a probability threshold of
45%, 0.81 precision (PPV), 0.98 True Positive Rate (also, "recall"/"sensitivity") and 0.19 False
Discovery Rate are demonstrated.
(F) AUC ROC of a model trained with only a subset of top 12 most predictive features reveals a
stable performance with the selected final features.

961
962 ***Figure 5: The contribution of individual miRNAs to the predictor of ALS diagnosis.***
963 (A) Mean absolute SHapley Additive exPlanations (SHAP) values   break down the impact of specific
964 miRNAs on ALS disease predictor output in the held-out cohort. (B) Illustration of the relationship
965 between the miRNA levels (low-blue to high-red), SHAP values and the impact on the prediction in the
966 held-out cohort.
967
968
969

Figure 6: A multi-disease miRNA-based prediction model displays a superior diagnostic power over the binary models. A 3-fold cross-validated RFE with Extra Tree Classifier reveals that 16 features out of the original 132 approximate the same weighted mean one-vs-rest ROC AUC. (B) Fitting a Gradient Boosting multi-class classifier ("one-vs-all" strategy) on the training set. The multi-disease classifier achieved a weighted "one-vs-all" ROC AUC of 0.92, 0.91, 0.89 for each fold, respectively. Mean AUC of 90%±7% is obtained, indicating an overall good fit of the soft-classifier to all classes. Variance of the curve is shown in gray. (C) Model generalizability by ROC AUC per class in the held-out set (AUC of 0.76 for controls, 0.97 for FTD and 0.86 for ALS class), reassuring good accuracy for the soft-classifier over all three classes (micro-average AUC of 0.88 and macro-average AUC of 0.87), ensuring the model is not overfitting. (D) Confusion matrix (with a one-vs-rest strategy) in the held-out data. Interestingly, 15/19 control subjects that were falsely classified were classified as "ALS". It can be observed that of the 16 false positives in 'ALS' class, 93.75% were actually healthy control. (E) a Venn diagram of miRNAs shared in the three classification models.

1021
1022
Figure 7: The contribution of individual features miRNAs shared and disease-specific miRNA
predictors. (A) SHAP analysis explains how features impact the multi-disease predictor output, namely,
class probabilities. Average impact (mean absolute SHAP values) of miRNAs on model output for
features, ordered according to their importance over all classes. (B-C) Combining feature importance with
feature effects to illustrate the relationship between the value of the feature and the impact on the
prediction, for a specific class; each point is a SHAP value for a feature and a specific subject. The
position on the y-axis is determined by the feature and scattered on the x-axis by the SHAP value. The
color represents the value of the feature from low (blue) to high (red). For example, the levels of mir-1-3p
equally influence predictions of FTD and ALS, with negligible contribution to predicting 'controls'. miR-326
and mir-629-5p contributes to the FTD predictor more than ALS, whilst high expression of mir-206
increases the predicted ALS risk (while having no effect on the risk of FTD). High values of miR-326, a
miRNA inflammatory regulator, increases the predicted FTD risk while miR-185-5p has the reversed
impact with higher values reducing the risk of FTD.
1036
1037

1038
Figure 8. AUC values for different miRNA classifiers for discriminating FTD vs control (A) and ALS vs
controls (B) in the held-out data. The classifiers used in (A) were either the 13 selected in the FTD model
in our data, a combination of miR-34a-5p, miR-345-5p, miR-200c-3p and miR-10a-3p selected in
Kmetzsch et al., 2020 (Kmetzsch *et al.*, 2021), or a combination of miR-335/let-7e, miR-99b/let-7e and
miR-9-3p/miR-181a selected in Sheinerman et al., 2017 (Sheinerman *et al.*, 2017); the classifiers used in
(B) were either the 12 selected in the ALS model in our data, a combination of miR-34a-5p, miR-345-5p,
miR-200c-3p and miR-10a-3p selected in Kmetzsch et al., 2020 or a combination of miR-206/miR-31,
miR-206/miR-125b and miR-99/miR-338-3p, selected in Sheinerman et al., 2017.

Supplementary tables and figures

Group Name	Age	Sex	Before Exclusion		After Exclusion		Age
			Mean Age	Group Size	Mean Age	Group Size	
ALS cases (n=206)	64.4±11.01, 95% CI [62.9, 65.9]	F	65.9	84	66.6	82	64.9±10.4, 95% CI [63.47, 66.35]
		M	63.3	122	63.8	120	
ALS controls (n=102)	49.9±13.68, 95% CI [47.25, 52.55]	F	51.1	73	55.3	59	55.7±10, 95% CI [53.46, 57.94]
		M	46.8	29	57.0	18	
FTD cases (n=169)	65.58± 8.37, 95% CI [64.32, 66.84]	F	66.8	59	67.3	58	65.75±8.1, 95% CI [64.53, 66.97]
		M	64.9	110	64.9	110	
FTD controls (n= 56)	60.96± 13.28, 95% CI [57.48, 64.44]	F	61.1	30	65.6	26	65.55± 7.3, 95% CI [63.49, 67.61]
		M	60.8	26	65.6	22	

Supplementary Table 1. Age and sex characteristics - before and after exclusion by age (age-based QC)

Predictor	Single Feature AUC
miR-423-5p	0.69
miR-125b-5p	0.69
miR-26a-5p	0.68
miR-107	0.68
miR-185-5p	0.64
miR-629-5p	0.62
let-7d-3p	0.61
miR-379-5p	0.61
miR-361-5p	0.6
let-7c-5p	0.6
miR-326	0.58
miR-378a-3p	0.56
miR-484	0.55

Supplementary Table 2. *Predictive power of selected features when used as a single predictor for FTD on held-out data. Among the most predictive features are miRNAs expressed in the brain, such as miR-26a-5p, miR-125b-5p and let-7c-5p.*

Predictor	Single Feature AUC
miR-186-5p	0.75
miR-223-3p	0.73
miR-23b-3p	0.72
miR-454-3p	0.72
miR-1-3p	0.71
miR-206	0.65
miR-103a-3p	0.62
miR-185-5p	0.61
miR-370-3p	0.56
miR-181b-5p	0.54
let-7i-5p	0.44
miR-320a	0.39

1096
1097 **Supplementary Table 3.** Predictive power of selected features, when used as a single predictor for ALS
1098 diagnosis on held-out data.
1099
1100

Predictor	Single Feature weighted one-vs.-all AUC
miR-1-3p	0.71
miR-185-5p	0.7
miR-186-5p	0.69
miR-629-5p	0.65
miR-206	0.65
miR-423-3p	0.65
miR-378a-3p	0.62
let-7d-3p	0.62
miR-339-5p	0.61
miR-23b-3p	0.6
miR-484	0.58
miR-148a-3p	0.57
miR-107	0.57
miR-361-5p	0.56
miR-326	0.55
miR-24-3p	0.45

1101
1102 **Supplementary Table 4.** *List of most predictive features and their predictive power (on held-out data)*
1103 *when used as a single predictor for ALS-FTD*

1121
Supplementary Figure 1: QC of prognostic factors in the meta-cohort. Depicting heterogeneity of
prognostic factors in the four different groups in the study, before (upper) and after (lower) exclusion of 38
outlier subjects under the age of 40. While the univariate distribution of age in some sub-groups overlap,
the difference in the shape of the age distributions may reflect a possible bias induced by age (B). The
total standardized differences in mean age across sub-groups was reduced by 68% after exclusion. (A),
(D) Boxplot age quartiles and variation of subjects by group - indicating skewness and variability outside
the upper and lower quartiles of age in some groups. After outlier exclusion, the groups "ALS-ctr" and
"FTD ctr" are more comparable and the high variability in "FTD ctr" is reduced. (B), (E) Distribution of age
conditioned by group: estimating the shape of the Probability Density Function (PDF) of age by non-
parametric Gaussian kernel density estimate. Outlier removal has increased the overlap of the different
PDFs. (C), (F) Mean age conditioned by gender and group. The different groups in the study are more
balanced in terms of age and gender after age-outlier removal.

1134
1135
1136 ***Supplementary Figure 2.*** *t-SNE analysis of control subjects (A) and all subjects (B) presenting de-*
1137 *separation between different control groups and between disease groups and merged control group.*
1138